Association of single-nucleotide polymorphism 3 and c.553G>T of APOA5 with hypertriglyceridemia after treatment with highly active antiretroviral therapy containing protease inhibitors in HIV-infected individuals in Taiwan

Clinical Infectious Diseases

Volumn 48, Issue 6, 2009, Pages 832-835

  Chang, Sui Yuan ^a,b   Ko, Wei Shin ^a   Kao, Jau Tsuen ^a,b   Chang, Lan Yang ^d   Sun, Hsin Yun ^c   Chen, Mao Yuan ^c   Hsieh, Szu Min ^c   Sheng, Wang Huei ^c   Chang, Shu Fang ^a   Liu, Wen Chun ^c   Wu, Cheng Hsin ^c   Hsu, Hui Jen ^b   Kao, Chuan Liang ^a,b   Lee, Chun Nan ^a,b   Hung, Chien Ching ^c   Chang, Shan Chwen ^c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b Department of Laboratory Medicine ^*  (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d ACADEMIA SINICA   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATAZANAVIR; EFAVIRENZ; INDINAVIR; INDINAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; APOA5 PROTEIN, HUMAN; APOLIPOPROTEIN A;

ADULT; AGED; APOA5 GENE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN; TRIACYLGLYCEROL BLOOD LEVEL; GENETICS; MIDDLE AGED; POINT MUTATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APOLIPOPROTEINS A; FEMALE; HAPLOTYPES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; POINT MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; TAIWAN; YOUNG ADULT;

EID: 62449147005     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/597099     Document Type: Article

References (14)

1. Calza L, Manfredi R, Farneti B, Chiodo F. Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy. Int J Antimicrob Agents 2003; 22:54-9.
2. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-8.
3. an Leth F, Hall DB, Lange JM, Reiss P. Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine. HIV Med 2006; 7:347-50.
4. Merkel M, Loeffler B, Kluger M, et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 2005; 280:21553-60.
5. Talmud PI, Hawe E, Martin S, et al. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Gen 2002;11:3039-46.
6. Kao IT, Wen HC, Chien KL, Hsu HC, Lin SW. A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum Mol Gen 2003;12:2533-9.
7. Tarr PE, Tafte P, Bleiber G, et al. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis 2005;191:1419-26.
8. Fauvel J, Bonnet E, Ruidavets JB, et al. An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 2001; 15:2397-406.
9. Foulkes AS, Wohl DA, Frank I, et al. Associations among race/ethnicity,ApoC-III genotypes, and lipids in HIV-l-infected individuals on antiretroviral therapy. PLoS Med 2006;3:e52.
10. Guardiola M, Ferre R, Salazar J, et al. Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5 - 1131T>C gene variation. Clin Chem 2006;52:1914-9.
11. Klos KL, Hamon S, Clark AG, Boerwinkle E, Liu K, Sing CF. APOA5 polymorphisms influence plasma triglycerides in young, healthy African Americans and whites of the CARDIA Study. J Lipid Res 2005; 46:564-71.
12. Matsunaga A, Arishima H, Niimura H, et al. Strong linkage disequilibrium and association of - 1131T>C and c.553G>T polymorphisms of the apolipoprotein A5 gene with hypertriglyceridemia in a lapanese population. Circ I 2007;71:746-52.
13. Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003;17:2603-14.
14. Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT study:a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-l-infected patients. J Acquir Immune Defic Syndr 2004; 35:22-32.